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Antibiotic prophylaxis has been, since 1960s, one of the management options in treating vesicoureteral reﬂux. The purpose of this
review article is to provide a concise overview of the rational for antiobiotic prophylaxis and to discuss the various agents used.
Some of the current controversies regarding use of antibiotics for reﬂux will also be presented.
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1. INTRODUCTION
Once vesicoureteral reﬂux (VUR) has been diagnosed, the
basic premise in management is to prevent further ascending
urinary tract infections (UTI) which may, if left untreated,
lead to pyelonephritis. Pyelonephritis, in turn, would lead
to potential renal damage [1]. Based on the work of
Jean Smellie et al. in 1960s, use of antibiotic prophylaxis was
foundtobehelpfulinreducingtherecurrencerateofurinary
tract infection in children with VUR [2]. Subsequently,
several long-term studies have demonstrated the validity of
the concept [3–7]. The basis for the antibiotic prophylaxis in
patients with VUR was the fact that, ultimately, reﬂux in low
grades (I through III) was recognized to resolve over time
and thus maintenance on low-dose antibiotic would prevent
or reduce the risk of urinary tract infection until such time
that the reﬂux would disappear [8]. The goal of this article is,
therefore,toreviewthemanagementofVURusingantibiotic
prophylaxis, its advantages and disadvantages based on a
review of the literature. The various antibiotic used for
prophylaxis in VUR will be discussed.
2. THE EVOLUTION OF ANTIBIOTIC PROPHYLAXIS IN
THE MANAGEMENT OF PATIENTS WITH VUR
Regurgitation of urine from the bladder up into the ureter
and renal collecting system has been recognized since early
times [9]. VUR became identiﬁed as an etiologic factor
for pyelonephritis from the classic studies carried out by
Hutch, who in 1952, studied a group of paraplegic patients
diagnosed with neurogenic dysfunction of the bladder and
VUR. Reﬂux of infected urine into the upper urinary tract
was postulated to be the cause of chronic and progres-
sive renal damage [10]. Later, in 1959, Hodson observed
that reﬂux seemed to be more common in children with
urinary tract infections and that there was a correlation
between reﬂux and chronic pyelonephritis as documented
byVCUG(voidingcystourethrogram)andIVU(intravenous
urogram) [11]. As the association between VUR and uri-
nary tract infection became more established, additional
experimental studies demonstrated the role of bacterial
infection in causing renal damage in patients found to have
VUR [12–14].
Historically, the initial approach to treating patients
with reﬂux was observational without continuous antibiotic.
Treatment was oﬀered only as infections occurred. Unfortu-
nately this approach demonstrated that renal damage could
occur in patients who had had only one infection and that
furtherrenaldamagewasmorelikelytooccurinkidneysthat
were noted to have parenchymal lesions but could also occur
in normal kidneys. Lenaghan reported that most infections
occurred within the ﬁrst ﬁve years after the initial diagnosis
[15]. In light of the high rate of new kidney damage noted in
children treated with intermittent antibiotic therapy, it was
suggested that prophylactic antibiotic be used. Lenaghan’s
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in children which also demonstrated a high rate of new scar
formation in children who were observed oﬀ continuous
antibioticprophylaxisbutwithknownreﬂux[16].Thisstudy
found that new renal damage occurred in 12.5% of children
with normal kidneys, whereas 62% of scarred kidneys
showed progression of the damage as infections were treated.
A number of subsequent studies showed that progression of
scarring in patients with reﬂux could occur in the face of
recurrenturinarytractinfection[17,18].N.P.Goldraichand
I. H. Goldraich, in 1992, showed that, in a large prospective
study children with VUR of grades I through V treated
with antibiotic prophylaxis, a relatively low rate of new scar
formation (3%) was found and this was seen only in cases
where urinary tract infection occurred [19]. The Southwest
Pediatric Nephrology Study Group demonstrated that in a
relatively small group of patients with grade 1–3 reﬂux fol-
lowed for ﬁve years, 12 patients (10.7%) developed new scars
on Intravenous Urogram intravenous urogram (IVU) in the
face of breakthrough infections [20]. Skoog et al. observed
a large cohort of patients (545) on continuous low-dose
antibiotic prophylactic for up to ten years. A relatively low
rate of progressive scarring in the kidneys was noted (0.5%)
mostly occurring in children with breakthrough infection
[21]. Current recommendations for antibiotic prophylaxis
in children have been formalized by the AUA guideline
panel on the management of primary VUR in children [22].
Recommendations from the guidelines were that children
with VUR grade I through IV could be initially managed
medically with continuous antibiotic prophylaxis because of
fewer risks, in the short term, and that surgery would be
recommended for children who experienced breakthrough
infections.
More recently the concept of stopping antibiotic prophy-
laxis after a certain age has been evaluated as parents have
increasingly become weary of long-term medication intake
andconcernshavebeenraisedaboutsideeﬀectsandbacterial
resistance. Based on the ﬁndings that, by age 4, renal scarring
was unlikely to occur in the face of urinary tract infection,
cessation of antibiotic prophylaxis was felt to be reasonable
in children beyond the age of 5 [23, 24]. Cooper et al.
evaluated a group of 51 patients with reﬂux with a mean
age of 8.6 years who were not treated with prophylactic
antibiotic [25]. Despite the fact that reﬂux persisted in the
majority of these patients, only a small number of patients
(11%) developed a subsequent urinary tract infection. No
new renal scars were noted as documented by ultrasound,
which, however, may not be the most accurate modality
to ascertain for renal lesions. Unfortunately, no long-term
double blinded randomized study has been carried out to
compare the eﬃcacy of antibiotic prophylaxis versus no
antibiotic prophylaxis in patients diagnosed with VUR based
on the degree of reﬂux. In addition, the data is still not
entirelyclearwithregardtothecomparisonbetweensurgical
therapy and antibiotic prophylaxis. The International Reﬂux
Study in Children (IRSC) failed to demonstrate a clear
advantage of any of these two forms of management [26].
The major limitations of the study were that not all grades of
reﬂux were managed by either modality, since higher grades
of VUR were treated surgically thus introducing a serious
selection bias. Currently, medical management of VUR still
remainscommonlypracticedforyoungerpatientswithlower
grades of VUR as the randomized studies are being set up.
3. ANTIBIOTICS USED FOR PROPHYLACTIC
TREATMENT IN PATIENTS WITH VUR
A relatively small number of antimicrobials are used to
treat urologic conditions in children, the most common
ones being used for antibiotic prophylaxis in the face
of VUR are trimethoprim-sulphamethoxasole (TMP/SMX),
nitrofurantoin, and penicillin derivatives amoxicillin. The
advantage of these antibiotics is that their active form or
metabolites are excreted in the urine thus keeping the urine
free of bacteria. Guidelines for administrations will not be
reviewed but it should be kept in mind that only penicillin
derivatives are used in younger children under 2 months
of age because the immaturity of the newborn liver and
kidneys results in a slower metabolism and excretion of
these medications [27]. Allergic reactions to antimicrobials
should always be a concern. A family history is helpful
in determining which child may actually be allergic to a
medication. Allergic reactions manifest themselves as either
urticaria, diﬀuse skin rash, or, more rarely, anaphylaxis.
Subcutaneous skin testing may resolve the question of an
allergicreactiontomedicationbutsincethetestingitselfmay
be associated with some risk of allergic reaction this should
be performed under controlled conditions by an allergist. A
5% cross allergenicity between penicillin and cephalosporin
should also be recognized [28]. In general, however, children
who have mild or delayed allergic reaction to one of these
classes of antimicrobials are usually able to tolerate agents in
other classes.
Bacterial drug resistance is a growing problem world-
wide. In 1980s, widespread recognition of the issue came
about with the widely reported vancomycin resistant staphy-
lococcal aureus infection found in cases of community
acquired infection [29]. The incidence of drug resistance
has clearly increased over the last 20 years and has become
a major health issue. Control of antimicrobial resistance is
clearly a multifaceted task involving hospital policy, indi-
vidual provider practice, and patient compliance. Guidelines
that have been developed by the Joint Committee on
Antimicrobial Resistance to help decrease the emergence
of drug resistance organism include a careful use of broad
spectrum antibiotic, the tailoring of therapy to sensitivity
proﬁles,andtheavoidanceofunnecessaryprolongedtherapy
[30].
Wewillreviewthespeciﬁcantimicrobialsusedinpatients
with VUR for prophylaxis of infections. These include
penicillins, TMP-SMX, and nitrofurantoin.
The penicillin class of antimicrobials includes natural
penicillins (V and K), amino penicillins (ampicillin and
amoxicillin), the beta-lactamase resistant penicillins (methi-
cilin, nafcilin, oxacillin, dicloxacillin), and the antipseu-
domonal penicillins (carbenicillin, ticarcillin, azlocilin, and
mezlocillin). The natural penicillins are used to prevent
and treat infections caused by group A streptococci and
S pneumonia. These medications are now rarely used forMarc Cendron 3
prophylaxis because of their limited commercial availability
and because resistance patterns have increased. Amino
penicillinshavebecomethemostcommonlyusedpenicillins.
They are the drug of choice in treating enterococcal urinary
tract infection and can be used for prophylaxis in infants
underage2months.Theseagentsareusuallyeﬀectiveagainst
most bacteria susceptible to Penicillin G as well as some
Penicillin G resistant gram negative bacilli [31]. Amino
penicillins are excreted primarily by the kidney. Ampicillin
is available both in oral and intravenous formulation but
Amoxicillin is only available as an oral agent. Amoxicillin
has better bioavailability than ampicillin because more of
it is absorbed from the digestive tract. A higher percentage
of unabsorbed oral ampicillin remaining in the gut alters
gut ﬂora frequently leading to GI upset and diarrhea
which may be a concern in younger children. A higher
rate yeast infections has also been noted. Beta-lactamase-
resistant penicillins are usually not used for prophylaxis as
are the antipseudomonal penicillins. Reactions to penicillins
are relatively rare and include hypersensitive reactions,
neurotoxicity, nephrotoxicity, and hematologic toxicity [32].
Trimethoprim/sulfamethoxazole is a combination agent
that inhibits the production of bacterial folic acid, thereby
blockingDNAsynthesis.Itisthemostwidelyusedoutpatient
antibiotic agent used for prophylaxis in children with
vesicoureteral reﬂux. While trimethoprim (Primsol) alone
has a similar antibacterial activity to sulfamethoxazole, the
spectrum of activity expands when the drugs are combined.
In addition, resistance develops less quickly in the combined
formulation than with either drug alone [33]. Sulfamethox-
azole and trimethoprim are both absorbed rapidly after all
administration.Themajorityofsulfamethoxazoleundergoes
hepatic metabolism to inactive metabolites, while approx-
imately half of the absorbed trimethoprim is converted
hepatically into inactive metabolites. Most of the active and
inactive drug is then excreted by the kidney into the urine
[34].
The adverse reactions associated with this combination
of drug are most often caused by the sulfa component.
These reactions include hypersensitivity reaction (ranging
from a mild rash to severe Stevens-Johnson exfoliative
reaction which may be severe and life threatening), severe
photosensitivity reaction, and hematologic toxicity that
presents as agranulocytosis or hemolytic anemia, prompt-
ing the recommendation that a complete blood count be
obtained in children who are taking sulfa medications for
extended periods of time. Sulfonamides are contraindicated
in children younger than 2 months of age because the
sulfa moiety from the drug can displace bilirubin from
its natural albumin binding site, predisposing infants to
hyperbilirubinemia [35].
Nitrofurantoin is an agent widely used for the prophy-
lactic management of VUR. While it is most commonly
administeredinanoralformulation,aparenteralformisalso
available. It is well absorbed orally and undergoes signiﬁcant
hepatic degradation to inactive metabolites. Because of its
extended metabolism and relatively poor tissue penetration,
nitrofurantoin is used solely as a urinary tract desinfectant
since it will achieve bacteriocidal concentration only in
urine. [33]. Although its exact mechanism of action is
unknown, nitrofurantoin is thought to inhibit bacterial
acetyl coenzyme A, thereby interfering with carbohydrate
metabolism. It may also disrupt bacterial cell wall synthesis.
Nitrofurantoin is usually eﬀective in treating staphylococci,
streptococci and most community acquired gram negative
uropathogens. Despite its widespread use, bacteria rarely
develop resistance to nitrofurantoin. This is most probably
due to the fact that the drug does not achieve signiﬁcant
levels in intestinal or vaginal tissues and does not alter
the normal ﬂora in these areas [36]. The most common
side eﬀect associated with nitrofurantoin is GI upset with
nausea, vomiting, or diarrhea. Use of the microcrystalline
formula and administration with meals usually eliminates
thesesideeﬀects.Arare,moreseveresideeﬀectispulmonary
ﬁbrosis, which is most likely to occur after long-term
therapy (months to years) and can present acutely with
episodic coughing and/or dyspnea which would warrant a
full evaluation. Hemolytic anemia can occur in patients with
glucose-six-phosphate dehydrogenase deﬁciency as well as in
infants under one month of age.
Cephalosporins are rarely used for antibiotic prophy-
laxis unless patients have shown resistance to TMP/SMX.
Because of their broad activity against community acquired
pathogen, this class of antimicrobial is usually used for
surgical prophylaxis or for acute treatment of urinary tract
infection. Cephalosporins provide a reasonable antimicro-
bial activity against most gram positive and gram negative
bacteria. Use of prophylaxis is usually not recommended
as the medications tend to be expensive. However, some
cephalosporins including Cephalexin have prolonged uri-
nary concentration and may be helpful for short-term
antibiotic prophylaxis.
Fluoroquinolones inhibit action of the essential bacterial
enzyme DNA gyrase which consequently prohibits main-
tenance of the superhelical twist in the double stranded
DNA causing rapid cell death [37]. One important clinical
aspect of the antibacterial spectrum of ﬂuoroquinolones is
their eﬀectiveness in treating hospital acquired organisms.
These antimicrobials have good pharmacokinetic qualities
which include rapid absorption from the intestinal tract,
good tissue penetration, and good intracellular diﬀusion.
Long-term use of ﬂuoroquinolones in a pediatric population
has been reported to be eﬀective and safe in patients with
cystic ﬁbrosis [38]. Ciproﬂoxacin in children seems to be
well tolerated with no signiﬁcant evidence of arthropathy,
bone abnormalities, and no serious adverse side eﬀects [39].
However, ﬂuoroquinolones have not become an acceptable
form of antibiotic prophylaxis given their expense and given
the risk for possible emergence of resistant organism to this
class of antimicrobials [40].
4. THEDOWNSIDESOFANTIBIOTICPROPHYLAXISIN
THE MANAGEMENT OF VUR
Three interrelated issues come into play when consider-
ing prophylactic antibiotic therapy for VUR: compliance,
eﬃcacy, and long-term side-eﬀects of chronic antibiotic
administration. Let us examine each of these issues. A recent4 Advances in Urology
report indicate that long-term administration of a daily
antibioticmaynotbecarriedoutascarefullyandconsistently
as one would hope. Hensle et al. in a review of patterns of
care based on health insurance data showed that only 17%
of patients were at least 80% compliant with prophylactic
treatment [41]. In addition, as time goes by, compliance
with antibiotic intake has been shown to go down by the
ﬁrst year follow-up visit [42]. Eﬃcacy of antibiotic therapy
in reducing the rate of urinary tract infection is hard to
evaluate as no long-term, randomized placebo-controlled
studies have, to date, been published. The Cochran Database
Systematic Review meta-analysis reported that there was
no signiﬁcant diﬀerence in risk for urinary tract infection
between daily antibiotic prophylaxis and no prophylaxis or
between intermittent (3 days per week) prophylaxis and no
prophylaxis [43]. The report also found no diﬀerence in
the risk of renal parenchymal damage between the various
treatment options. In addition the review indicated that 30
to 50% of patients on antibiotic prophylaxis were reported
to have a UTI within 5 years. In a recent multicenter,
randomized study of antibiotic prophylaxis treatment of
patients with lower grades of VUR, Garin et al. showed a
similar one year urinary infection rate between patients
who were treated with or without antibiotic prophylaxis:
23.6% of children with grade 1 through 3 reﬂux received
antibiotics and acquired a urinary tract infection while
22.4% of those on no antibiotic prophylaxis acquired one.
Interestingly, those patients on antibiotic prophylaxis were
found to have a higher rate of pyelonephritis upon follow-up
[44]. Recurrent infections are, therefore, a worrisome issue
in patients with VUR maintained on antibiotic prophylaxis.
Sj¨ ostr¨ om reported a rate of breakthrough urinary tract
infections in patients with reﬂux up to 47% of case [45].
Whether or not these infections are harmful in the long term
is unclear but this persistent ability to acquire urinary tract
infectionclearlybringsintoquestiontheeﬃcacyofantibiotic
prophylaxis and the role of host susceptibility to infections.
If one looks at the ability of prophylactic antibiotic to reduce
the risk forrenal scarring, Reddy et al. reported no diﬀerence
in occurrence of renal damage amongst patients with VUR
randomized to receive either antibiotic prophylaxis or no
antibiotics [46]. Finally, it would appear that outcomes
seem to be rather similar in patients randomly assigned to
medicalorsurgicalmanagement[47].Inarecentopen-label,
randomized study from Italy, antibiotic prophylaxis was not
found to be eﬀective in reducing the rate of pelonephritis
recurrence and the incidence of renal damage in young
children with VUR grades II, III, IV [48].
5. CONCLUSION
Antibiotic prophylaxis still seems to be a reasonable man-
agement option after initial diagnosis of VUR especially in
children under age ﬁve who may be more susceptible to
renal damage if an ascending urinary tract infection occurs.
Issuesofnoncompliance,questionableeﬃcacy,potentialside
eﬀects and allergic reactions, and antimicrobial resistance
have now brought into question use of antibiotic prophylaxis
in the management of VUR. Further, uncertainty is built
into the fact that prediction of reﬂux resolution varies
from patient to patient and may involve other factors
than anatomic ones. The complex nature of the interaction
between VUR and UTIs and their eﬀects on the kidneys
make the identiﬁcation of those patients at risk for ascending
urinary tract infection and subsequent renal damage the
biggest challenge in managing VUR. Since the available
data is still not suﬃcient in providing objective guidelines
for use of antibiotic prophylaxis in managing VUR, fur-
ther long-term, randomized placebo-controlled studies are
clearly needed to allow better insight into this form of
management. In the ﬁrst year after diagnosis, consistent,
low-dose administration of antibiotics may be helpful in
reducing the rate of urinary tract infection provided that the
right antibiotic is administered keeping in mind the caveat
of such a treatment, mainly the rising rate of antimicrobial
resistance [48]. It should be noted that cranberry juice may
have a role in reducing the rate of UTIs [49]. Parents of
children diagnosed with VUR should be apprised of the
potential side eﬀects of the medications used for prophylaxis
of UTIs and of the other options available for treatment.
Reassurance as to the relatively low rate of complication rate
seenwithantibioticprophylaxisshouldbeemphasized.Until
such studies show unequivocally that antibiotic prophylaxis
is ineﬀective in preventing urinary tract infection and renal
damage, antibiotic prophylaxis still remains a viable option
in the management of VUR [50].
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